



(51) International Patent Classification:

C12N 15/113 (2010.01) C12N 9/22 (2006.01)
C12N 9/10 (2006.01)

(21) International Application Number:

PCT/US2024/021866

(22) International Filing Date:

28 March 2024 (28.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/492,845 29 March 2023 (29.03.2023) US
63/505,906 02 June 2023 (02.06.2023) US

(71) Applicant: **SCRIBE THERAPEUTICS INC.** [US/US];
1150 Marina Village Parkway, Alameda, California 94501
(US).

(72) Inventors; and

(71) Applicants: **FERNANDES, Jason** [US/US]; c/o Scribe
Therapeutics Inc., 1150 Marina Village Parkway, Alameda,
California 94501 (US). **HIGGINS, Sean** [US/US]; c/
o Scribe Therapeutics Inc., 1150 Marina Village Park-
way, Alameda, California 94501 (US). **DENNY, Sarah**
[US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village
Parkway, Alameda, California 94501 (US). **WHITE, Ross**
[US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Vil-
lage Parkway, Alameda, California 94501 (US). **OAKES,**
Benjamin [US/US]; c/o Scribe Therapeutics Inc., 1150 Ma-


rina Village Parkway, Alameda, California 94501 (US).
CHARLES, Emeric Jean Marius [FR/US]; c/o Scribe
Therapeutics Inc., 1150 Marina Village Parkway, Alameda,
California 94501 (US). **WRIGHT, Addison** [US/US];
c/o Scribe Therapeutics Inc., 1150 Marina Village Park-
way, Alameda, California 94501 (US). **STAAHL, Brett T.**
[US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village
Parkway, Alameda, California 94501 (US). **DEITER, Fred**
[US/US]; c/o Scribe Therapeutics Inc., 1150 Marina Village
Parkway, Alameda, California 94501 (US).

(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylv-
ania Ave., NW, Suite 700, Washington, District of Colum-
bia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: REPRESSOR FUSION PROTEIN SYSTEMS



(57) Abstract: Provided herein are gene repressor systems comprising repressor fusion proteins, such as repressor fusion proteins comprising DNA binding proteins, in some cases catalytically dead CRISPR proteins and guide nucleic acids (gRNA), useful in the repression of genes. Also provided are methods of using such systems to repress transcription of genes.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*